See other bills
under the
same topic
                                                      PRINTER'S NO. 3562

THE GENERAL ASSEMBLY OF PENNSYLVANIA


HOUSE RESOLUTION

No. 507 Session of 2002


        INTRODUCED BY YUDICHAK, MANN, PALLONE, SOLOBAY, STABACK,
           BELARDI, BELFANTI, CAPPELLI, CORRIGAN, COSTA, COY, CREIGHTON,
           CRUZ, DALEY, DeWEESE, EACHUS, D. EVANS, FRANKEL, FREEMAN,
           GABIG, GEORGE, GRUCELA, HARHAI, HASAY, HENNESSEY, HERSHEY,
           JAMES, KELLER, LAUGHLIN, LESCOVITZ, MELIO, MICHLOVIC,
           PICKETT, PISTELLA, READSHAW, SAINATO, THOMAS, TIGUE, TRELLO,
           WASHINGTON, J. WILLIAMS, G. WRIGHT AND YOUNGBLOOD,
           APRIL 8, 2002

        REFERRED TO COMMITTEE ON INTERGOVERNMENTAL AFFAIRS,
           APRIL 8, 2002

                                  A RESOLUTION

     1  Memorializing the Food and Drug Administration to review the top
     2     50 prescription drugs as determined by direct-to-consumer
     3     spending each year to determine if they can be switched to
     4     over-the-counter status.

     5     WHEREAS, The Food and Drug Administration (FDA) has the
     6  authority to conduct evaluations each year of various
     7  prescription drugs to determine whether the drugs may be
     8  switched to over-the-counter (OTC) status; and
     9     WHEREAS, The findings of these evaluations describe the
    10  safety and effectiveness of each drug, its benefit-to-risk ratio
    11  and whether clear and understandable labeling can be written for
    12  self-medication without intervention of a health care
    13  professional; and
    14     WHEREAS, Drugs that are limited to prescription use under a
    15  New Drug Application can be exempted from that limitation if the


     1  FDA determines the prescription requirements to be unnecessary
     2  for the protection of public health; and
     3     WHEREAS, The cost of a prescription drug is growing at a
     4  double-digit rate, making it increasingly difficult to provide
     5  affordable broad-based prescription benefits to low-income and
     6  middle-income individuals; and
     7     WHEREAS, According to the FDA:
     8         Drugs found appropriate for over-the-counter sales have
     9         an increasingly vital role in the United States health
    10         care system by providing consumers easy access to certain
    11         drugs that can be used safely for conditions that
    12         consumers can self-treat without the help of a health
    13         care practitioner. Consumers have access to more than
    14         100,000 OTC drug products encompassing more than 800
    15         active ingredients and covering more than 100 therapeutic
    16         categories or classes;
    17  and
    18     WHEREAS, The availability of OTC drugs saves approximately
    19  $20 billion each year, taking into account prescription costs,
    20  doctor visits, lost time from work, insurance costs and travel;
    21  therefore be it
    22     RESOLVED, That the House of Representatives of the
    23  Commonwealth of Pennsylvania memorialize the FDA to review the
    24  top 50 prescription drugs as determined by direct-to-consumer
    25  spending each year to determine if they can be granted OTC
    26  status; and be it further
    27     RESOLVED, That copies of this resolution be transmitted to
    28  the FDA and to each member of Congress from Pennsylvania.


    B25L82BIL/20020H0507R3562        - 2 -